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Abstract
Background: Length and intensity of signal transduction via cytokine receptors is precisely regulated. Degradation of
certain cytokine receptors is mediated by the ubiquitin ligase SCF(bTrCP). In several instances, Janus kinase (Jak) family
members can stabilise their cognate cytokine receptors at the cell surface.
Principal Findings: In this study we show in Hek293 cells that Jak2 binding to the growth hormone receptor prevents
endocytosis in a non-catalytic manner. Following receptor activation, the detachment of phosphorylated Jak2 induces
down-regulation of the growth hormone receptor by SCF(bTrCP). Using c2A human fibroblast cells we show that both
growth hormone-induced and constitutive growth hormone receptor endocytosis depend on the same factors, strongly
suggesting that the modes of endocytosis are identical. Different Jak2 RNA levels in HepG2, IM9 and Hek293 cells indicate
the importance of cellular concentration on growth hormone receptor function. Both Jak2 and bTrCP bind to neighbouring
linear motifs in the growth hormone receptor tail without the requirement of modifications, indicating that growth
hormone sensitivity is regulated by the cellular level of non-committed Jak2.
Conclusions/Significance: As signal transduction of many cytokine receptors depends on Jak2, the study suggests an
integrative role of Jak2 in cytokine responses based on its enzyme activity as well as its stabilising properties towards the
receptors.
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Introduction
In mammalian cells the Janus kinase (Jak) family of protein
tyrosine kinases comprises Jak 1,2,3 and Tyk2. All Jak family
members are widely expressed except for Jak3 that is restricted to
cells of the hematopoietic system. Jak molecules associate non-
covalently with a membrane-proximal region in cytoplasmic tails
of cytokine receptors and play crucial roles in the initial steps of
cytokine signalling [1,2].
At the C-terminus, Jak family members contain the tyrosine
kinase domain preceded by a pseudokinase domain. The N-
terminal half of Jak comprises a postulated FERM domain (four-
point-one, ezrin, radixin, moesin) that binds to cytokine receptors
and a potential SH2 domain [3]. Specific mutations in the FERM
domain inhibit cytokine receptor association and concomitantly
abrogate Jaks’ ability to respond to ligand binding. Binding of the
FERM domain to receptors has also been proposed to assist in cell
surface localisation of several cytokine receptors [4,5,6,7,8,9].
Growth hormone (GH) is a multifunctional, clinically important
cytokine hormone that acts through its type I cytokine receptor,
the growth hormone receptor (GHR). The type I cytokine receptor
family further includes the prolactin (Prl) receptor, the erythro-
poietin (Epo) receptor, and the thrombopoietin (Tpo) receptor
[10,11]. All cytokine receptors lack intrinsic kinase activity.
Instead, a conserved proline-rich domain in their cytosolic tail,
box-1, functions as a binding site for Jak family members. In the
case of GHR, ligand binding results in the activation of Jak2
molecules [12] that in turn phosphorylate each other’s tyrosine
residues , the receptor’s cytosolic tail and downstream signalling
molecules [13]. Both liganded and unoccupied GHRs are
endocytosed via clathrin-coated vesicles and subsequently trans-
ported via endosomes to lysosomes [14]. Previously, we have
shown that both endocytosis and transport to lysosomes require an
active ubiquitin conjugation system and a 10-amino acid motif
(UbE-motif inside the conserved box-2 region) in the cytosolic tail
of GHR [15]. The SCF(bTrCP) ligase drives endocytosis and
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non-conventional UbE motif of GHR [16].
GHR signalling depends on relative rotation of the pre-
dimerised receptor subunits aligning two Jak2 molecules upon
GH binding [17,18]. Recent studies show that the Jak family also
plays non-catalytic roles in regulating the cellular localisation and
trafficking of cytokine receptors [6,19]. For the GHR, increased
Jak2 expression levels increase the fraction of mature GHRs [9].
GHR endocytosis provides an important means to control GH
sensitivity. Patients with cancer-induced wasting are relatively
GH-insensitive and have low GH binding protein titers, indicative
for rapid endocytosis of GHRs [20]. It is therefore important to
understand the cellular mechanisms involved in the regulation of
GHR endocytosis.
Here, we demonstrate that Jak2 binding specifically inhibits
GHR endocytosis, independent of its kinase activity. Studies by the
group of Ihle have shown that phosphorylation of tyrosine 119 of
Jak2 abrogates the interaction of Jak2 with several cytokine
receptors [21,22,23]. Based on this and our own experiments, we
hypothesise that GH stimulation releases Jak2 from the GHR.
Combining fractionation studies with bioluminescence resonance
energy transfer (BRET), we show that Jak2 activation indeed
results in release of phosphorylated Jak2 from the GHR, after
which the GHR is allowed to internalise via SCF(bTrCP)-
mediated endocytosis and to be degraded.
Results
Jak2 specifically inhibits GHR endocytosis independent of
its kinase activity
Recently, we showed that the E3 ligase SCF(bTrCP) is required
for GHR endocytosis via the UbE-motif of the GHR [16]. Other
studies revealed that Jak2 stabilises the GHR [9,24]. In Fig. 1D the
different binding motifs are illustrated. To investigate whether
Jak2 mediates GHR stabilisation by inhibiting GHR endocytosis,
we expressed Jak2 in GHR-expressing Hek293 cells and incubated
the cells with Cy3-GH to monitor GHR endocytosis. Cy3-GH
uptake was strongly inhibited in cells expressing exogenous Jak2,
while cells that did not express exogenous Jak2 contained less Cy3-
GH, all of it being intracellular en route to the lysosomes (EV)
(Fig. 1A). Exogenously expressed Jak2 did not interfere with
clathrin-mediated endocytosis in general as is shown in Fig. 1A for
transferrin, right panels, where we compared Cy3-GH and
transferrin uptake. Hek293 cells that did not express GHR
showed no Cy3-GH labelling (not shown), indicating that the
entire fluorescent label originated from GHR activity. Thus,
(over)expression of Jak2 causes a clear disruption of GH/GHR
endocytosis.
To investigate whether the endocytosis inhibition depends on
the interaction between GHR and Jak2, we took advantage of a
study by Funakoshi-Tago and co-workers who showed that
replacing a tyrosine residue with a glutamic acid at position 119
abrogates Jak2 binding to a subset of cytokine receptors, including
the GHR [21]. Fig. 1A, lower panel, shows that expression of
Jak2(Y119E) did not affect Cy3-GH uptake, indicating that Jak2-
GHR interaction is needed for the inhibition of endocytosis of the
GHR. We then asked whether Jak2 kinase activity is required. As
Cy3-GH activates both GHR and Jak2, we transfected the cells
with a DNA construct expressing only the N-terminal half of the
molecule including FERM and SH2 domains, devoid of the
(pseudo)kinase domains. As seen in Fig. 1A, Jak2(1-525) inhibited
GHR endocytosis similar to wild-type Jak2. These data are in full
agreement with work of Deng et al. who showed that binding of
Jak2 is sufficient to inhibit GHR down-regulation [24]. To confirm
that Jak2 indeed inhibits GHR endocytosis we determined the
initial uptake rates of
125I-GH in cells co-transfected with GHR
and Jak2. As seen in Fig. 1B, about 40% of
125I-GH was
endocytosed within 10 min, whereas less than 10% endocytosed if
Jak2 was co-expressed. This uptake rate is very similar if GH is
bound to a GHR that lacks the bTrCP binding site (UbE motif).
Co-expression of Jak2 had no significant additive effect on GHR
endocytosis. Together, these results demonstrate that overexpres-
sion of Jak2 inhibits GHR endocytosis.
To further substantiate the results we expressed the various Jak2
species in the GHR-expressing cell line. Fig. 1C, upper panel,
shows that both wild-type and Jak2(1-525) increased the steady
state levels of several fold, dependent on the efficiency of
transfection. The increase was solely due to decreased endocytosis
of the mature (130kD) GHR, because the steady state levels of
GHR in the endoplasmic reticulum (110kD) were unchanged.
Notably, although expressed to the same level, the Jak2 binding
mutant Jak2(Y119E) had little effect on the steady state of GHR.
Incubation with GH slightly increased the apparent molecular
weight of mature GHR in the presence of wild-type Jak2 but had
no effect if the truncated form of Jak2 was co-expressed. Next, we
analysed the Jak2-GHR interaction. As expected, both wild-type
and truncated Jak2, but not Jak2(Y119E) co-immunoprecipitated
with the GHR (Fig. 1C, panel 4). Exogenous Jak2(1-525) was
unable to phosphorylate the GHR upon GH addition, while
Jak2(Y119E) induced a very low level of phosphorylation as
compared to wild-type Jak2, probably due to a low residual affinity
of the mutant Jak2 for box-1 (lanes 4, 6, 8), indicating that Jak2-
GHR binding is essential for GHR phosphorylation (Fig. 1C).
Together, we conclude that Jak2 binding to the GHR inhibits
GHR endocytosis independent of Jak2 kinase activity.
Jak2 acts upstream of SCF(bTrCP)
Based on our conclusion that Jak2 binding is sufficient to inhibit
GHR endocytosis, we hypothesised that Jak2 must leave the GHR
before the endocytosis machinery, including SCF(bTrCP) and
clathrin, can proceed [16]. Although GHR does not seem to be an
essential target for ubiquitination, the receptor becomes ubiqui-
tinated during the process of endocytosis [25]. Here, we use GHR
ubiquitination to measure progression of the GHR in the
endocytosis process. In this scenario, it is expected that bTrCP
gene silencing prevents GHR (K48) polyubiquitination, while
clathrin silencing might accumulate (K48-ubiquitinated) GHR at
the cell surface as it acts downstream of SCF(bTrCP). Dependent
on the effectiveness, silencing of bTrCP caused a 5–10 fold
accumulation of the mature (130kD) GHR at steady state, whereas
its synthesis (110kD) remained unchanged. Upon bTrCP silencing,
especially if GH was added to the cells, GHR ubiquitination was
clearly inhibited (Fig. 2A). To ascertain that this polyubiquitin
signal was K48-linked as is expected if SCF(bTrCP) is the
ubiquitin ligase, we overexpressed wild-type and mutant ubiquitin
that cannot make K48 and K63 polyubiquitin chains (K48R and
K63R), respectively [26,27,28,29]. As seen in Fig. 2B, ubiquitin
K48R overexpression could not form poly-ubiquitin chains on
GHR, whereas transfection of ubiquitin K63R had no effect.
Thus, very likely bTrCP is involved in K48-linked ubiquitination
of GHR during endocytosis.
Cargo selection into clathrin-coated pits is a general mechanism
for cells to specifically transport membrane proteins into
endosomes. Previously, we showed that GHR endocytosis occurs
clathrin-mediated [30,31]. In Fig. 2A, right panel, we show that
silencing of clathrin indeed caused a very strong accumulation of
ubiquitinated GHRs, especially if the cells were treated with GH.
Quantification of the amounts of GHR is difficult due to variable
Jak2 and GHR Endocytosis
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To ascertain that the ubiquitin signals originate from GHR we
used 1% boiling SDS buffers in all ubiquitination experiments to
lyse the cells and to prevent (ubiquitinated) proteins to associate to
GHR. We conclude that GHR ubiquitination occurs before
endocytosis and depends on SCF(bTrCP) activity.
If Jak2 binding prevents the activity of SCF(bTrCP), exogenous
Jak2 should accumulate GHR at the cell surface in a non-
ubiquitinated state. Therefore, we overexpressed wild-type and
mutant Jak2 in the GHR-expressing cell line and measured GHR
ubiquitination. Upon wild-type Jak2 and Jak2(1-525) overexpres-
sion, GHR was stabilised, but GHR ubiquitination was decreased,
demonstrating a strong inhibition of GHR ubiquitination (Fig. 2C,
lane 4). To quantify the effects we measured the ratios of
ubiquitinated GHR over total mature GHR: both in absence and
presence of GH the ubiquitination of GHR was 4–10 times lower
if either wild-type Jak2 or Jak2(1-525) was overexpressed
compared to control cells (empty vector). As expected, Ja-
k2(Y119E) showed GHR ubiquitination comparable to control
cells. We conclude that Jak2 binding inhibits GHR ubiquitination
and probably acts upstream of SCF(bTrCP) and clathrin.
Phosphorylated Jak2 dissociates from the GHR
So far, we have shown that Jak2 inhibits GHR endocytosis non-
catalytically. According to our hypothesis, Jak2 needs to detach
from the receptor to allow endocytosis. As shown by Funakoshi-
Tago et al., phosphorylation of Y119 of Jak2 induces Jak2
dissociation of several cytokine receptors [21]. This implies that
GH stimulation results in Jak2 release. As many studies have been
performed with cell lines expressing exogenous GHR, large
Figure 1. Jak2 inhibits GHR endocytosis. A. GHR-expressing Hek293 cells were transfected with empty vector (EV), Flag-Jak2, Flag-Jak2(Y119E) or
Flag-Jak2(1-525). One coverslip was incubated for 15 min with Cy3-GH at 37uC, fixed and stained with anti-Flag (left panels). For EV- and Jak2-
transfected cells, cells were also incubated with Cy3-GH and Alexa488-transferrin (Tf) for 15 min at 37uC (right panel). Bar, 5 mm. B. Hek293 GHR or
GHR(UbE mutant)-expressing cells were transfected with Jak2 DNA or empty vector and, after 2 days, incubated for 2h on ice with 180 ng/ml
125I-GH.
To measure uptake kinetics unbound label was removed and the cells were incubated at 37uC for 10 min. C. Hek293 cells were transfected as in 1A
and treated with GH for 15 min at 37uC as indicated. Total cell lysates (TCL, upper panel) and GHR immunoprecipitations (lower panel) were analysed
on western blot (WB) using anti-Flag, or anti-phosphotyrosine (pY). 130, mature GHR; 110, precursor GHR. Data are representative of three
independent experiments. D. Diagram showing the different binding motifs in the dimerised GHR; Jak2 binds Box1, TrCP binds UbE). The
transmembrane domains are the dimerisation domains.
doi:10.1371/journal.pone.0014676.g001
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might disturb the control of endocytosis that is based on a
stoichiometric relation between Jak2 and GHR.
Human IM9 lymphoblasts have detectable levels of endogenous
GHR and have been used in many cytokine receptor studies. An
important property of this cell line is the fact that GHR is only
endocytosed in presence of GH. If IM9 cells contain sufficient
amounts of Jak2 to accumulate endogenous GHRs at the cell
surface, we expect that GH stimulation triggers GHR endocytosis
by Jak2 phosphorylation on Y119 and detachment from the GHR.
Testing the endogenous Jak2-GHR interaction by co-immuno-
precipitation failed, probably due to low efficiency of the
antibodies. Therefore, we based our experiments on the findings
of Behrmann et al., who showed that Jak1 and 22 mainly occur
membrane-bound, dependent on their ability to associate with
cytokine receptors [32]. As Jak2 can only become phosphorylated
if associated with a cytokine receptor [1,33], we assume that
phosphorylated Jak2, if present in the cytosol, has been released
from GHRs. First, we established the relative distribution of total
endogenous Jak2: 80% was membrane-bound (Fig. 3A, left lanes).
No GHR was detectable in the cytosolic fraction (not shown).
Treatment with GH did not change the overall Jak2 distribution
(this is expected as Jak2 binds to many different substrates) but, the
fraction of phosphorylated Jak2 remained almost 50% higher in
the cytosol compared to that in the membrane fraction as
measured over a period of 60 min (Fig. 3A, right lanes). These
results indicate that phosphorylated Jak2 dissociates from the
GHR upon GH stimulation. As it is unknown in what priority and
proportion the different tyrosine residues in Jak2 are phosphor-
ylated, it is difficult to assess why not all phosphorylated Jak2 is in
the cytosol.
To ascertain that GH-induced GHR endocytosis (degradation)
in IM9 cells depends on the ubiquitin system as previously shown
for GHR endocytosis in various tissue culture cells, we used the
proteasomal inhibitor MG132 [25]. Pre-treatment of IM9 cells
with MG132 indeed completely inhibited GH-induced GHR
degradation (Fig. 3B, lanes 7–9). To investigate whether GH-
induced endocytosis depends on Jak2 activity, we inhibited
endogenous Jak2 kinase activity with the kinase inhibitor
staurosporin and treated the cells with GH. Previously, it has
been shown that 1 mM staurosporin abolished GHR phosphory-
lation in CHO cells [34]. Fig. 3C shows the same result for Jak2
phosphorylation. In control cells GH induced complete degrada-
tion of the GHR within 60 min, while staurosporin treatment
stabilised the mature GHR (Fig. 3B). The immunoprecipitations
shown in Fig. 3B were performed after boiling in 2% SDS and
reducing agents to exclude that the observed loss of GHRs resulted
from a shift to the detergent-insoluble fraction. Whether or not the
Figure 2. SCF(bTrCP) and Clathrin act downstream of Jak2. A. GHR-expressing Hek293 cells were either silenced for GFP (negative control),
bTrCP or clathrin, and then treated for 15 min with GH at 37uC as indicated. GHR immunoprecipitations were analysed for ubiquitination. In the lower
part of the figure the efficiency of silencing is visualised using anti-bTrCP or anti-Clathrin. B. Hek293 cells were transiently transfected with HA-tagged
wild-type ubiquitin, ubiquitin K48R or ubiquitin K63R. Total cell lysates (TCL) and GHR immunoprecipitates were analysed on western blot using the
indicated antibodies. EV, empty vector. C. Cells were transfected as in Fig. 1A and then treated for 15 min with GH at 37uC as indicated. GHR was
immunoprecipitated from SDS-boiled lysates, and analysed for ubiquitination. 130, mature GHR, 110, precursor GHR. At the bottom of the figure the
ratios of ubiquitinated versus 130kD-GHR are given. All data in this figure are representative of three independent experiments.
doi:10.1371/journal.pone.0014676.g002
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stage as suggested by Goldsmith et al. [35], in any case the final
result is an almost complete GH-induced degradation of GHR
after 60 min. The results support the hypothesis that Jak2 kinase
activity is required for GHR endocytosis. Although previous
studies indicate an enhanced interaction between GHR and Jak2
upon GH stimulation [36], the conditions differ in timing and
expression levels, indicating that the GHR-Jak2 interaction is
dynamic during GH stimulation. This is also supported by the
current view that signalling complexes preassemble at the plasma
membrane [32,37].
Resonance energy transfer techniques have recently emerged
that allow the study of the dynamics of interactions of proteins in
living cells [38], such as BRET. BRET has been extensively used
to study a wide range of protein interactions, such as GPCRs
[39,40] and insulin receptor [41]. We have made use of this
technology to study the effect of GH on the interaction between
GHR and Jak2. We created and validated the interaction partners,
Jak2, N-terminally fused to YFP (YFP-Jak2), and GHR, C-
terminally fused to Renilla luciferase (GHR-Rluc). As a negative
control, Jak2 Y119E, which does not bind GHR, was N-terminally
fused to YFP (YFP-Jak2 Y119E). Hek293-TR cell lines constitu-
tively expressing GHR-Rluc, as well as Jak2-YFP (wt or Y119E),
under a doxycycline inducible promoter as described in the
Methods section were used. In the absence of doxycycline, no
acceptor protein (YFP-Jak2) is expressed, and, therefore, it is a
condition of donor only (GHR-Rluc). Doxycycline induction
resulted in the expression of YFP-Jak2 that (as expected) induced
accumulation of GHR (compare lanes 2–4 with lane 1).
Expression of the binding mutant, YFP-Jak2 Y119E, did not
stabilise GHR-Rluc, (lanes 5 and 6). As seen in Fig. 4B BRET
measurement detected a clear interaction between GHR-Rluc and
YFP-Jak2, consistent with the association of Jak2 with the
cytoplasmic tails of GHR in absence of GH. As predicted, no
BRET signal could be detected in the cell line where YFP-Jak2
Y119E was expressed. Addition of GH, elicited a fast (time
interval: 0–4 min) reduction of the BRET signal (of 4666%) when
compared to basal state. After 10 min the BRET ratio stabilised at
the level of 65% (6563%) of the basal signal. The short
stimulation with GH was sufficient to cause a decreased migration
of the mature GHR in the gel (Fig. 4A, lanes 3 and 4). Although it
is important to realise that BRET cannot distinguish between a
change in conformation that results in an increased distance
between donor and acceptor, and dissociation events, our results
are in agreement with a scenario where, at early time points after
GH stimulation, Jak2 dissociates from the receptor due to its
phosphorylation, but soon after it re-associates in a dynamic
fashion, probably due to phosphorylation/dephosphorylation
cycles. Since the Jak2 expression affects the levels of GHR,
neither saturation nor competition assays could be performed. In
addition, use of a kinase-inactive Jak2, that is unable to leave the
GHR, would generate biased results due to unpredictable
conformational changes in the BRET assay; therefore, no
quantitative data regarding the interaction were obtained.
Decreased Jak2 activity in coated pits
If Jak2 detaches after GH stimulation, we expect Jak2 activity to
be absent in the GHR complexes that are about to be recruited
into the coated pits. To test this we inhibited endocytosis at the
coated pits by either methyl-b-cyclodextrin (MbCD) or by
silencing clathrin. MbCD depletes cholesterol from the plasma
membrane and inhibits clathrin-coated pit budding. This causes
inhibition of internalisation of the transferrin receptor by 85%
[42]. Fig. 5A shows inhibition of Cy3-GH uptake after treatment
with MbCD as compared to non-treated cells. Next, we stimulated
with GH and measured both GHR- and STAT5 phosphorylation.
As seen in Fig. 5B, GHR phosphorylation was strongly inhibited in
MbCD-treated cells as compared to non-treated cells that
expressed comparable amounts of GHRs (lower panel, lanes 2
and 4). In addition, phosphorylation of STAT5, a major
downstream signal transduction molecule, was decreased (upper
Figure 3. GH induces Jak2 phosphorylation and release from
the GHR. A. IM9 cells were treated with GH for 1 h at 37uC as indicated,
followed by cell fractionation. Membrane (M) and cytosol (C) fractions
were immunoprecipitated for Jak2 and analysed with the indicated
antibodies. The ratio of phosphorylated Jak2 (pJak2) and total Jak2 was
calculated for each fraction. Total cell lysates were analysed for Hsp90, a
cytosolic marker. B. IM9 cells were pretreated with vehicle (dimethyl-
sulfoxide), staurosporin or MG132 for 1 h and stimulated with GH at
37uC as indicated. Total cell lysates (TCL) and GHR immunoprecipita-
tions were analysed on western blot with the indicated antibodies. C.
IM9 cells were pretreated with staurosporin (Stau) for 1 h followed by
incubation with GH at 37uC as indicated. Jak2 immunoprecipitations
were analysed with the indicated antibodies. Data in A, B, and C are
representative of three independent experiments.
doi:10.1371/journal.pone.0014676.g003
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efficiency of GH-GHR interaction indicating a strong reduction of
Jak2 activity at this stage of endocytosis. If clathrin was silenced, a
40% reduction of GHR phosphorylation was measured (Fig. 5C,
lower panel). The reduction in GHR phosphorylation was not as
prominent as for MbCD, probably due to the efficiency of gene
silencing. These data support our hypothesis that GHRs that are
about to be recruited by the endocytosis machinery can no longer
be phosphorylated, suggesting the absence of Jak2 in the GHR
complex. Although we measure a clear reduction of GHR
phosphorylation under conditions of inhibited endocytosis with
GH bound, an alternative explanation could be a failure of the
GH-bound GHR to undergo the necessary conformational change
to realign JAK2 monomers in the absence of cholesterol in the
plasma membrane as well in the absence of a functioning clathrin
mediated endocytosis pathway.
GH-induced and constitutive endocytosis use the same
endocytosis mechanism
To compare GH-induced and GH-independent ‘‘constitutive’’
GHR endocytosis we used a c2A, human fibroblast cell line that
stably expresses GHR and is Jak2-deficient (c2A_GHR). This cell
line was used to make a variant cell line that produces low
numbers of Jak2 (c2A_GHR_Jak2). Upon stimulation of both cell
lines with GH, quantification of mature GHR levels showed that
after 90 min about 50% of the GHRs were degraded in
c2A_GHR_Jak2 cells, while in c2A_GHR cells GHR steady state
levels remained unchanged (Fig. 6A). These data indicate that GH
is able to increase GHR endocytosis and lower the GHR steady
state level only in the presence of Jak2. Without GH stimulation,
the GHR steady state level in both cell lines is defined by
constitutive GHR endocytosis, which results in much lower GHR
levels in c2A_GHR cells. We hypothesised that GH-induced as
well as constitutive GHR endocytosis use the same endocytosis
mechanism. If that is the case, GH-induced GHR endocytosis
should (i) use the UbE motif and the SCF(bTrCP) ligase, (ii)
depend on clathrin and (iii) not depend on the phosphorylation
status of the GHR. The experiments of Fig. 3B already showed
that both GH-induced and constitutive GHR endocytosis depend
on the ubiquitin system. For the second criterion we asked whether
GH-induced GHR endocytosis occurs via clathrin-coated pits. We
depleted c2A_GHR_Jak2 cells for clathrin, treated the cells with
GH and compared the change in mature GHR levels between
control and clathrin-depleted cells. Clathrin depletion strongly
inhibited GH-induced GHR endocytosis, demonstrating that GH-
induced GHR endocytosis is clathrin-dependent (Fig. 6B). Subse-
quently, we asked whether GH-induced GHR endocytosis
depends on the same E3 ligase as constitutive GHR endocytosis.
Depletion of bTrCP resulted in inhibition of GHR endocytosis for
both constitutive and GH-induced GHR endocytosis (Fig. 6B).
Quantification showed that GH-stimulated GHR endocytosis is
reduced from 50% to about 20% under conditions of either
clathrin or bTrCP depletion, indicating that both proteins are
required for GH-induced GHR endocytosis.
Previous data indicated that bTrCP uses the non-canonical
UbE motif for GHR endocytosis, although the canonical DSG
motif is present in the GHR cytosolic tail. The question whether
the DSG motif is involved in GH-induced endocytosis is relevant,
because in case of Prl-induced PrlR degradation, the DSGxxS
motif acts as endocytosis motif [43]. To clarify this point for the
GHR we used either UbE or DSGxxS GHR mutant cell lines,
derived from the c2A cells expressing low numbers of Jak2. Upon
GH treatment we observed that mutation of the UbE motif
resulted in inhibition of GH-induced GHR endocytosis (Fig. 6C),
indicating that the UbE motif is essential for GH-induced GHR
endocytosis. Mutating the DSGxxS motif did not inhibit GH-
induced GHR endocytosis (Fig. 6C). We conclude that both GH-
induced GHR endocytosis and constitutive GHR endocytosis
depend on bTrCP binding via the UbE-motif rather than via the
DSGxxS motif. This implies that GH-triggered tyrosine phos-
phorylation of the GHR is irrelevant in our model. To explicitly
address this issue we used our c2A cell line expressing both low
amounts of Jak2 and a mutant GHR in which all cytosolic tyrosine
Figure 4. GH induces Jak2 release from GHR. Hek293-TR stable
cell lines expressing GHR-Rluc and YFP-Jak2 (wt or Y119E) were seeded
24 h before the measurements; doxycycline was added in order to
stimulate the expression of YFP-Jak2 constructs. BRET measurements
were started immediately after GH addition (interval t=0–4 min), or
10 min later (interval t=10–14 min). A. Cells were lysed, and the
proteins expression levels of the BRET pair in the cell lysates, were
assessed by western blot, using the indicated antibodies. Data are
representative for three independent experiments. Panel B shows the
BRET ratios expressed in mBU, representative of 8 independent
measurements 6 S.E.M. (* significantly different from GHR-Rluc+YFP-
Jak2 wt, minus GH condition, p,0.01; W significantly different from
GHR-Rluc+YFP-Jak2 Y119E condition, p,0.01; Y significantly different
from GHR-Rluc+YFP-Jak2 wt, plus GH [0–4 min] condition, p,0.01).
doi:10.1371/journal.pone.0014676.g004
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6D confirmed that mutation of all tyrosines did not affect GH-
induced GHR endocytosis.
In summary, we found that GH-induced GHR endocytosis and
constitutive GHR endocytosis share the same characteristics. Both
pathways are ubiquitin system-, clathrin- and bTrCP-dependent
and use the UbE motif for GHR endocytosis. These data strongly
suggest that the two pathways are similar.
Relative high Jak2 levels compared to bTrCP correlate
with high GH sensitivity of cells
The data presented in this study imply that both bTrCP2 and
Jak2 bind to membrane-proximal linear motifs of the GHR at the
cell surface. Therefore, relative expression levels of these two
proteins might be important determinants for the endocytosis of
GHR and possibly other cytokine receptors. If cells have relatively
high Jak2 levels compared to bTrCP2, Jak2-dependent cytokine
receptors will be stabilised at the plasma membrane. Conversely,
relatively low Jak2 levels will result mainly in constitutive
endocytosis. We tested three different cell lines for mRNA and
protein levels of Jak2 and bTrCP2: IM9 cells that completely
depend on GH for GHR endocytosis, and Hek293 and HepG2
cells that exhibit mainly constitutive endocytosis of exogenous
GHRs. Using qRT-PCR we found that the Jak2 mRNA level
relative to the bTrCP2 level is considerably higher in IM9 cells
compared to Hek293 and HepG2 cells (Fig. 7). Although mRNA
levels do not necessarily reflect protein levels, the data support our
hypothesis that endogenous Jak2 protein levels contribute to the
GH responsiveness of cells, not only because of their kinase
potential but also their homeostatic effect.
Discussion
Previous studies on cytokine receptors showed that Jak family
members are able to stabilise GHR, Epo, G-CSF, and Tpo
receptors in addition to the type I interferon a/b receptor
(IFNAR1) and the oncostatin M receptor [4,5,9,19,24,44]. For
Epo receptor it has been shown that Jak2 binding in the ER
induces proper folding and efficient trafficking to the cell surface
[4]. Studies on Tpo receptor describe that Jak2 stabilises the
mature Tpo receptor on the cell surface without affecting
maturation kinetics [19]. For GHR, it has been shown that Jak2
enables efficient processing of precursor receptor to mature
receptor [45]. Whereas Jak2 does seem to affect neither Tpo nor
Epo receptor endocytosis, Jak2 clearly inhibits GHR endocytosis.
The different effects of Jaks on cytokine receptors suggest that
cytokine receptors contain unique features in their cytoplasmic
tails to be differentially affected. Whether a common theme will
emerge, i.e. that the kinases stabilise their cognate receptors until
receptor activation, remains to be investigated. In summary, the
data of our study indicate the following scenario: Jak2 binding
prevents endocytosis until GH binding triggers Jak2 phosphory-
lation and its detachment from the GHR, presumably via the
phosphorylation of Y119 in Jak2. GHRs, synthesised in excess to
uncommitted Jak2, are continuously and bTrCP-mediated
endocytosed. Thus, the GHR depends on GH for endocytosis
only if Jak2 is bound. This is in agreement with the study of Deng
et al., who showed that at low concentration of Jak2 GHR
degradation depends on GHR activation [24].
Figure 5. Decreased Jak2 activity in coated pit. A. GHR-expressing
Hek293 cells were pretreated with MbCD for 1 h, incubated with Cy3-
GH for 30 min at 37uC and the fluorescence was visualised with a
confocal microscope. Bar, 5 mm. B. Cells were pretreated as in Fig. 4A,
followed by incubation for 15 min with GH at 37uC as indicated. Total
cell lysates (TCL, upper panel) and GHR immunoprecipitations (lower
panel) were analysed on western blot with the indicated antibodies.
130, mature GHR; 110, precursor GHR. C. Cells were silenced either for
clathrin or for GFP (as a negative control), followed by incubation for
15 min with GH at 37uC as indicated. Total cell lysates (TCL, upper
panel) and GHR immunoprecipitations (IP, lower panel) were analysed
on western blot with the indicated antibodies. 130, mature GHR; 110,
precursor GHR. Data are representative for two independent experi-
ments (B).
doi:10.1371/journal.pone.0014676.g005
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phosphorylation of a DSGxxS motif C-terminal of box-2 triggers
endocytosis and degradation [43,46]. Although such a conserved
motif is also present in GHR, we showed that it is not involved in
GH-induced endocytosis. The present study demonstrates that the
UbE motif is essential for both GH-induced and constitutive GHR
endocytosis. In addition, we find that the tyrosine residues of the
GHR are not involved in GHR endocytosis. This part is in
contrast to data by Deng et al. [24], who showed that
phosphorylation of cytosolic tyrosine residues is important for
GH-induced GHR endocytosis. Since the expression level of Jak2
is essential to be able to measure GHR endocytosis, a different
Jak2 expression level in our model system compared to the model
system of Deng et al. could explain the different findings.
In our proposed model, the release of phosphorylated Jak2 from
the GHR is induced by GH stimulation, after which bTrCP can
bind the GHR and select the receptor for endocytosis. This implies
that the role of Jak2 is upstream of bTrCP binding and subsequent
GHR endocytosis. However, the Jak2 release and subsequent
GHR endocytosis cannot be measured in cells overexpressing
GHR, because the level of exogenous GHR greatly exceeds the
number of endogenous Jak2. As a consequence, the vast majority
of GHRs is not in complex with Jak2 and will endocytose
Figure 6. GH-induced and constitutive GHR endocytosis share the same characteristics. A. c2A_GHR_Jak2 cells (left panel) and c2A_GHR
cells (right panel) were stimulated with 500 ng/ml GH for 90 min at 37uC as indicated. Total cell lysates (TCL) (lower panels) and GHR
immunoprecipitates (upper panels) were analysed on western blot with the indicated antibodies. B. c2A_GHR_Jak2 cells were transfected with
control siRNA (lanes 1 and 2), clathrin heavy chain siRNA (CHC) (lanes 3 and 4) or TrCP siRNA (lane 5 and 6). Cells were stimulated with 500 ng/ml GH
for 90 min at 37uC as indicated, after which total cell lysates (TCL) (3 lower panels) and GHR immunoprecipitates (upper panel) were analysed on
western blot with the indicated antibodies. C. c2A_Jak2 cells, stably transfected with wild-type GHR (WT), GHR mutated in its DSGxxS motif (DSG),
GHR mutated in its UbE motif (UbE) and GHR with all cytosolic tyrosine mutated into phenylalanine residues (Y-less) were stimulated with 500 ng/ml
GH at 37uC as indicated, after which total cell lysates (TCL) (2 lower panels) and GHR immunoprecipitates (upper panel) were analysed on western
blot with the indicated antibodies. Cell lines used in C are stably transfected with the indicated GHR constructs, resulting in clonal variation of Jak2
levels. Data in A and B are representatives of three independent experiments. Data in C are representatives of two independent experiments. D.
Quantification of the GH-induced GHR degradation (Y-less from experiment in C, and the data from the experiment in B), expressed as percentage of
mature GHR.
doi:10.1371/journal.pone.0014676.g006
Figure 7. mRNA levels of Jak2 and bTrCP2 in IM9, Hek293 and
HepG2 cells. mRNA levels were measured using qRT-PCR. Ratios of
Jak2/bTrCP2 are displayed of IM9, Hek293 and HepG2 cells as mean
values of six independent experiments 6 SD.
doi:10.1371/journal.pone.0014676.g007
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Alves dos Santos et al.. cellular model systems were used in which
GHR was overexpressed [47,48]. Therefore, the authors conclud-
ed that Jak2-binding does not induce GHR endocytosis, but it
cannot be excluded that Jak2 has an inhibitory effect on GHR
endocytosis. The same arguments apply for the observation that
endocytosis of GHRs that lack a functional box-1 is unaffected.
Moreover, Alves dos Santos et al. have shown Jak2 binding in the
endosomes, suggesting that Jak2 remains associated with the GHR
during the process of endocytosis. However, it is well possible that
this (small) amount of Jak2 has rebound after GHR endocytosis.
Our conclusion that Jak2 binding inhibits GHR ubiquitination
and probably acts upstream of SCF(bTrCP) and clathrin is based
on the K48 ubiquitination status of the GHR. If Jak2 detaches, the
activity of SCF(bTrCP) seems to increase due to GH-induced Jak2
phosphorylation. When Jak2(1-525) is over-expressed, no GH-
induced increased ubiquitination of the receptor occurs. This
could be justified by the fact that Jak2(1-525) lacks kinase activity
and, therefore, does not phosphorylate itself and consequently
does not detach. Overexpression of the Y119E mutant doesn’t
affect the GH-induced GHR increased ubiquitination since it does
not bind. Together, these date clearly support our model.
In addition to phosphorylation of Jak2, cells must have other
mechanisms available to respond to exogenous factors that also
induce Jak2 detachment in order to decrease GH sensitivity. These
scenarios are required when stresses impose survival mechanisms.
In these cases, stress-driven signal transduction pathways might
activate Jak2 to abrogate the GHR-Jak2 interaction and induce
rapid endocytosis via SCF(bTrCP). Alternatively, a protein that
interferes with the Jak2-GHR interaction could be up regulated. No
such factor has been identified for the Jak2-GHR interaction yet.
Our findings implicate that, in addition to the expression level of
GHR, the cellular concentration of free Jak2 is a major factor that
regulates the number of GHRs at the cell surface. A simple
explanation would be that the N-terminal half of Jak2, bound to
box-1, is sufficient to shield other functional motifs like the UbE
sequence, or prevent SCF(bTrCP) complex assembly. Evidence for
this scenario comes from a study from Pelletier et al., in which they
show that both box-1 and the UbE-motif are involved in Jak2
binding and activation [33]. The question whether both the UbE
and the box-1 positions can be occupied at the same time, by
bTrCP and Jak2 respectively, remains unanswered. The stoichi-
ometry of a kinase-competent complex requires the presence of two
Jak2 molecules, while an endocytosis-competent complex probably
requires two complete SCF(bTrCP) complexes with two neddylated
cullins. bTrCP acts as a dimer and possibly needs two UbE motifs
for productive binding. On the other hand, it might well be that one
Jak2 molecule on a GHR dimer is sufficient to block endocytosis
[17,49]. Our current experiments indicate that both Jak2 and
bTrCP can be present at the same time, since overexpression of
Jak2 did not affect bTrCP binding to the GHR, in pull-down
experiments with biotinylated GH (not shown). However, as
suggested by the BRET experiments, the system appears highly
dynamic. As endocytosis of monomeric GHR does not require the
ubiquitin system [17], only in vitro binding studies with dimeric
GHRs will elucidate the interplay between Jak2 and SCF(bTrCP).
As many genes have sexually dimorphic expression dependent
on either male pulsatile or female continuous patterns of GH
secretion [50], our model predicts that cellular Jak2 levels might
contribute to this; cells with high Jak2 levels and low GHR
expression, like IM9, respond mainly to GH spikes, because they
lose their GHRs temporarily, while liver cells with low Jak2 levels
and high GHR expression are continuously responsive for both
types of GH secretory patterns.
Materials and Methods
Materials, antibodies and DNA constructs
MbCD and staurosporin were purchased from Sigma. MG132
was obtained from Calbiochem. GHR antisera were described
before [14]. Monoclonal 4G10 anti-pY was obtained from Upstate
(Millipore). Monoclonal antibodies against Jak2 (AHO1352),
ubiquitin (clone FK2) and clathrin (C1860) were bought from
Biosource, Biomol and Sigma, respectively. Anti-STAT5 (C17) was
obtained from Santa Cruz Biotechnologies Inc. and anti-actin
(Clone C4) was obtained from MP Biomedicals Inc. Monoclonal
anti-Flag (M2) was from Sigma. Polyclonal anti-Jak2 was described
previously [34] and anti-bTrCP1 was described before [16]. Full-
length rabbit GHR cDNA in pcDNA3 has been described before
[14], just as GHR(S366A, S370A) (DSG mutant) [16]. The Flag-
tagged wild-type mouse Jak2 constructs were a generous gift from
Prof. Carter-Su (University of Michigan, Ann Arbor). Flag-Jak2(1-
525) was constructed by the introduction of a stop-codon using the
Quickchange mutagenesis kit from Stratagene. Jak2(Y119E), the
GHR in which all tyrosines were mutated to phenylalanines and the
GHR in which 326EFIxxD residues were mutated to alanine (UbE
mutant), were also produced using the same kit. Protein A-beads
were from Repligen. We cloned Jak2 into vector pSG213 for stable
expression in c2A cells. pSG213 was a kind gift of Prof. Melchior
(Zentrum fu ¨r Molekulare Biologie der Universita ¨t Heidelberg).
BRET contructs
Renilla Luciferase (Rluc)expression vectorwasa gift from Michel
Bouvier (Universite ´ de Montre `al). The primers were purchased
from Sigma-Genosys. We amplified the Rluc coding region with the
forward primer GATCGCGGCCGCATGACTTCGAAAGTT-
TATG and the reverse primer GATCTCTAGATTATTGTT-
CATTTTTGAGAACTCG. The Rluc-pcDNA3 construct was
generated by ligating the Rluc fragment into pcDNA3 (Invitrogen)
using Not1 and Xba1 restriction sites. GHR cDNA was amplified
from GHR-pcDNA3 expression vector [14] with the forward
primer, GATCGGTACCGCCACCATGGATCTCTGGCAG
and the reverse primer GATCCCAGTGTGCTGGTGGCAA-
GATTTTGTTCAG. The obtained PCR product was cloned in
frame with the Rluc coding sequence in the previously generated
Rluc-pcDNA3 vector, using Kpn1 and BstX1 restriction sites.
Expression from this vector, GHR-Rluc-pcDNA3, results in C-
terminally Rluc tagged GHR. The YFP sequence was amplified
from EYFP-N1 vector (Clontech), using the forward primer
GATCCTTAAGGCCACCATGGTGAGCAAG, and the reverse
primer, GATCGGTACCCTTGTACAGCTCGTCCATGCC
and the PCR product was cloned into the doxycycline inducible
promotor pcDNA4/TO (Invitrogen) using Afl2 and Kpn1
restriction sites. Jak2 (wt) and Jak2 (Y119E) were amplified from
pcDNA3-flag-Jak2(wt) and pcDNA3-Flag-Jak2 (Y119E) expression
vectors, respectively, using the forward primer GATCGGATC-
CATGGGAAATGGCCTGCC and reverse primer GATCGCG-
GCCGCCTATACTGTCCCGGATTTGATCC. The obtained
PCR products were cloned in frame with the YFP coding sequence
in the previously generated YFP-pcDNA4 vector, using the
restriction sites BamH1 and Not1. Expression from these vectors,
YFP-Jak2(wt or Y119E)-pcDNA4, results in N-terminally YFP
tagged Jak2.
Cell culture, transfections, and microscopy
Human embryonic kidney 293 (Hek293) cells, stably expressing
wtGHR were maintained in DMEM high glucose (4.5 g/l),
supplemented with 10% FCS, 100 U/ml penicillin, 100 mg/ml
streptomycin and 600 mg/ml G418 as described previously [16].
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streptomycin, containing 4.5 g/l glucose and 1 mM sodium
pyruvate. c2A cells were maintained in DMEM low glucose
(1.0 g/l), supplemented with 10% FCS, 100 U/ml penicillin,
100 mg/ml streptomycin. Stable cell lines with Jak2 in pSG213
were maintained in medium, supplemented with puromycin
(1 mg/ml), and stable cell lines with wtGHR with hygromycin
50 mg/ml). When indicated, the cells were pretreated with 10 mM
MbCD, 20 mM MG132 or staurosporin in serum free medium for
60 min at 37uC. Human GH was added at a concentration of
180 ng/ml. DNA transfections were performed using FuGene 6
(Roche, Applied Sciences) according to the manufacturer’s
instructions. Clathrin was silenced using the ON-TARGETplus
SMART-pool of Dharmacon (Thermo Fisher Scientific., Lafay-
ette, CO). bTrCP (1 and 2) was silenced with the ‘‘combi probe’’
and GFP siRNA was used as described before [16]. In all siRNA
transfections Lipofectamine 2000 (Invitrogen) was used according
to the manufacturer’s instructions. Microscopy studies were
performed as previously described [16].
Generation of stable cell lines for the BRET studies
Hek293 cells, stably expressing the Tetracycline Repressor
(Hek293-TR), were a gift from Dr. Madelon Maurice (Dept Cell
Biology, UMC Utrecht). The cells were transfected with GHR-
Rluc-pcDNA3 construct using Fugene 6 (Roche, Applied
Sciences), according to the manufacturer’s instructions. The
selection of clones expressing GHR-Rluc was done using
Geneticin (Invitrogen). Subsequently, double stable cell lines
expressing GHR-Rluc and YFP-Jak2 (wt or Y119E) were
generated, by transfecting YFP-Jak2 (wt or Y119E)-pcDNA4 in
the previously generated cell line expressing GHR-Rluc. The
selection of clones expressing GHR-Rluc and YFP-Jak2 (wt or
Y119E) was done using zeocin (Invitrogen). The generated BRET
cell lines were maintained in DMEM high glucose (4.5 g/l)
(Invitrogen), supplemented with 10% FCS (Invitrogen), 100 U/ml
penicillin (Invitrogen), 100 mg/ml streptomycin (Invitrogen),
600 mg/ml Geneticin (Invitrogen) and 100 mg/ml Zeocin (Invitro-
gen). The expression of YFP-Jak2 was induced by addition of
1 mg/ml doxycycline (Clontech) 24 h before the experiment.
Lysis and immunoprecipitations
For GHR-Jak2 co-immunoprecipitations, the cells were lysed in
20 mM Tris pH 8.0, 150 mM NaCl, 0.5% NP40, 1 mM PMSF,
10 mg/ml aprotinin, 10 mg/ml leupeptin. For phosphorylation and
ubiquitination experiments, the cells were lysed in 1% Triton X-
100 with inhibitors (1 mM EDTA, 1 mM PMSF, 10 mg/ml
aprotinin, 10 mg/ml leupeptin, 10 mM NEM, 1 mM Na3VO4
and 50 mM NaF). To prevent incomplete solubilisation or
association of ubiquitinated proteins for some experiments cells
were lysed in hot SDS sample buffer containing 1% SDS. Cell
lysates were centrifuged to pellet the nuclei and the supernatants
were used for GHR isolation in 1% Triton X-100, 0.5% SDS,
0.25% sodium deoxycholate, 0.5% BSA, and inhibitors via
immune precipitation with anti-GHR and protein A beads.
Immunoprecipitates were subjected to reducing SDS-PAGE and
transferred to Immobilon-FL polyvinylidenedifluoride membrane
(Millipore). Blots were immunostained with the indicated primary
antibodies followed by Alexa Fluor 680, Alexa-800 IRDye
conjugated anti-mouse or anti-rabbit antibodies. Detection was
performed with an Odyssey system (LI-COR Biosciences).
125I-GH binding and internalisation and cell fractionation
125I-GH binding and internalisation was performed as previ-
ously described [15]. Internalisation was expressed as a ratio
between iodinated GH inside and total. For cell fractionation, 10
7
(IM9) cells were incubated for 10 min with GH and washed with
cold PBS. Cell fractionation was performed as previously
described [32], except that we omitted the 12.500g centrifugation
step. After fractionation, the membrane and cytoplasmic fractions
were immunoprecipitated with polyclonal anti-Jak2, followed by
isolation using protein A beads. The samples were subjected to gel
electrophoresis and western blotting as described above.
BRET measurements
24 h prior to the measurements, cells were washed with
phosphate-buffered saline (PBS), and detached with trypsin-
EDTA. 4610
4 cells were reseeded in DMEM phenol-red free
medium (Gibco), containing 10% FCS, 100 U/ml penicillin,
100 mg/ml streptomycin per well of a 96-well plate (white cell
culture plate Nunc), in the presence or absence of doxycycline.
2610
5 cells treated in the same way were seeded per well in 24
wells plates and lysed 24 h after to evaluate the expression levels of
the BRET pairs. Before the BRET measurements the culture
medium was replaced by BRET assay buffer: PBS, 0,1% glucose,
25 mM Hepes. The substrate ViviRen (Promega) was then added
to each well in a final concentration of 60 mM. 30 sec before the
measurement started, 200 ng/ml hGH was added for the
indicated times points. Repeated readings at 475 nm and
535 nm (15 cycles, 0,5 sec interval time, 15 sec per reading), for
donor and acceptor emission, respectively, were taken at 37uC
with a Fluorstar Optima Fluorescence Plate Reader (BMG
LABTECH). BRET signal was expressed in milliBRET Units as
defined previously [39]. The BRET unit is the signal ratio 535/
475 nm obtained when the donor and acceptor are expressed (in
presence of doxycycline), subtracted from the ratio obtained under
the same experimental conditions, when only the donor partner
(fused to Rluc) is expressed (in absence of doxycycline). Two
ANOVA analyses of variance were performed with the statistical
program SPSS where the factors were compared in the presence/
absence of GH and at the time periods after GH addition.
RNA isolation and real time quantitative–PCR (qRT-PCR)
Total RNA from IM9, Hek293 and HepG2 cells was isolated
using RNeasy mini kit (Qiagen) according to the manufacturer’s
protocol. Synthesis of cDNA was carried out from 1 mg total RNA
in 20 ml reaction volumes using the iScript
TM cDNA synthesis kit
according to the manufacturer’s protocol (BioRad). Primers were
designed using primer select software of DNA star (Madison, WI)
accordingtotheparametersoutlined inthe BioRadi-cycler manual.
The specificity of each primer was confirmed by sequencing its
product. Rps19 and b-actin genes were used as the non-regulated
reference genes for normalisation of target gene expression.
Sequences of the used primers are for Jak2 TGAAGACCGG-
GATCCTACACACAGTT (forward) and GTCATACCGGCA-
CATCTCCACAC (reverse), for bTrCP2 CATGTTGCAGCGG-
GACTTTATTACC (forward) and GATCACTCGCTGCCAT-
TCTTTACAT (reverse), for Rps19 CCTTCCTCAAAAAGT-
CTGGG (forward) and GTTCTCATCGTAGGGAGCAAG (re-
verse), for b-actin. TCCCTGGAGAAGAGCTACG (forward) and
GTAGTTTCGTGGATGCCACA (reverse). Annealing tempera-
tures for Jak2, bTrCP2, Rsp19 and b-actin were 63.0, 62.0, 61.0
and 60.0uC, respectively. QRT-PCR was performed using BioRad
MyIQ detection system (BioRad) with SYBR green fluorophore.
Data analysis was carried out using the pair wise fixed reallocation
and randomisation test incorporated in the software program
REST-MCS [51] at 5% level of significance. Experiments were
performed in duplicate and values from six experiments were used
for data analysis.
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